Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression
Open Access
- 7 September 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (10), 2906-2917
- https://doi.org/10.1182/blood-2011-01-331694
Abstract
Endothelial cells (ECs) in blood vessels under formation are stabilized by the recruitment of pericytes, both in normal tissues and during angiogenesis in pathologic situations, including neoplasia. In the tumor vasculature, besides supporting the functionality of blood flow, pericytes protect ECs from antiangiogenic therapies, and have thus been implicated in clinical resistance to vascular targeting drugs. However, the molecular nature of the crosstalk between pericytes and ECs is largely unchartered. Herein, we identified pericyte-induced survival signals in ECs by isolation of vascular fragments derived from tumors that had been genetically or pharmacologically engineered to be either pericyte-rich or pericyte-poor. Pericytes induced the antiapoptotic protein Bcl-w in tumor ECs both in vivo and in vitro, thereby conveying protection from cytotoxic damage. The pericyte-dependent survival signaling in ECs was consequential to enforcement of an autocrine loop involving VEGF-A expression in ECs. Through molecular and functional studies, we delineated a signal transduction pathway in ECs downstream of integrin alpha(v) involving activation of NF-kappa B as the initiating event of the protective crosstalk from pericytes. Our elucidation of pericyte-derived pro-survival signaling in tumor ECs has potentially important implications for clinical development of antiangiogenic drugs, and suggests new therapeutic targets for rational multitargeting of cancer. (Blood. 2011; 118(10): 2906-2917)Keywords
This publication has 48 references indexed in Scilit:
- Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formationBlood, 2009
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic TherapyClinical Cancer Research, 2009
- Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis InhibitorsCancer Research, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Impact of vessel maturation on antiangiogenic therapy in ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte contentJCI Insight, 2007
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancerJCI Insight, 2006